Department of Anesthesiology, Division of Clinical and Translational Research (E.D.K., K.S.), and Department of Biochemistry and Molecular Biophysics (E.D.K.), Washington University in St. Louis, St. Louis, Missouri.
Drug Metab Dispos. 2013 Dec;41(12):2166-74. doi: 10.1124/dmd.113.053991. Epub 2013 Sep 25.
Plasma concentrations of orally administered methadone are reduced by the human immunodeficiency virus protease inhibitor combination ritonavir and lopinavir, but the mechanism is unknown. Methadone metabolism, clearance, and drug interactions have been attributed to CYP3A4, but this remains controversial. This investigation assessed the effects of acute (2 days) and steady-state (2 weeks) ritonavir-lopinavir on intravenous and oral methadone metabolism and clearance, hepatic and intestinal CYP3A4/5 activity (using the probe substrate intravenous and oral alfentanil), and intestinal transporter activity (using oral fexofenadine) in healthy volunteers. Plasma and urine concentrations of methadone and metabolite enantiomers, and other analytes, were determined by mass spectrometry. Acute and chronic ritonavir-lopinavir reduced plasma methadone enantiomer concentrations in half, with an average 2.6- and 1.5-fold induction of systemic and apparent oral methadone clearances. Induction was attributable to stereoselectively increased hepatic methadone N-demethylation, hepatic extraction, and hepatic clearance, and there was a strong correlation between methadone N-demethylation and clearance. Methadone renal clearance was unchanged. Alfentanil's systemic clearance and hepatic extraction, apparent oral clearance, and intestinal extraction were reduced to 25%, 16%, and 35% of control, indicating strong inhibition of hepatic and intestinal CYP3A activities. Ritonavir-lopinavir (acute > chronic) increased fexofenadine exposure, suggesting intestinal P-glycoprotein inhibition. No correlation was found between methadone clearance and CYP3A activity. Acute and steady-state ritonavir-lopinavir stereoselectively induced methadone N-demethylation and clearance, despite significant inhibition of hepatic and intestinal CYP3A activity. Ritonavir-lopinavir inhibited intestinal transporters activity but had no effect on methadone bioavailability. These results do not support a significant role for CYP3A or ritonavir-lopinavir-inhibitable intestinal transporters in single-dose methadone disposition.
口服美沙酮的血浆浓度会被人类免疫缺陷病毒蛋白酶抑制剂利托那韦和洛匹那韦降低,但具体机制尚不清楚。美沙酮的代谢、清除和药物相互作用归因于 CYP3A4,但这仍然存在争议。本研究评估了急性(2 天)和稳态(2 周)利托那韦-洛匹那韦对健康志愿者静脉内和口服美沙酮代谢和清除率、肝和肠 CYP3A4/5 活性(使用探针底物静脉内和口服阿芬太尼)以及肠转运体活性(使用口服非索非那定)的影响。通过质谱法测定美沙酮及其代谢物对映体和其他分析物的血浆和尿液浓度。急性和慢性利托那韦-洛匹那韦将美沙酮对映体的血浆浓度降低了一半,系统和口服美沙酮清除率的平均诱导倍数分别为 2.6 倍和 1.5 倍。诱导归因于立体选择性增加的肝美沙酮 N-去甲基化、肝提取和肝清除率,并且美沙酮 N-去甲基化与清除率之间存在很强的相关性。美沙酮肾清除率不变。阿芬太尼的全身清除率和肝提取率、口服表观清除率和肠提取率分别降低至对照的 25%、16%和 35%,表明肝和肠 CYP3A 活性受到强烈抑制。利托那韦-洛匹那韦(急性>慢性)增加了非索非那定的暴露量,表明肠 P-糖蛋白抑制。美沙酮清除率与 CYP3A 活性之间未发现相关性。尽管肝和肠 CYP3A 活性受到显著抑制,但急性和稳态利托那韦-洛匹那韦立体选择性地诱导了美沙酮 N-去甲基化和清除率。利托那韦-洛匹那韦抑制肠转运体活性,但对美沙酮的生物利用度没有影响。这些结果不支持 CYP3A 或利托那韦-洛匹那韦可抑制的肠转运体在单次剂量美沙酮处置中的重要作用。